技术指标
指标
数值
方向
MACD(12,26,9)
-0.015
卖出
RSI(14)
24.241
卖出
STOCH(KDJ)(9,3,3)
3.239
超卖
ATR(14)
0.114
低波动
CCI(14)
-146.703
卖出
Williams %R
99.370
超卖
TRIX(12,20)
-1.653
卖出
StochRSI(14)
0.000
超卖
搜索
VolitionRX Ltd
VNRX添加自选
0.847USD
-0.033-3.74%
收盘 07-28 16:00（美东）报价延迟15分钟
335.90K总市值
亏损市盈率 TTM
关键数据
0.927今开
0.974最高
397.74K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
100.30%换手率
0.880昨收
0.847最低
236.16K成交额
亏损市盈率静
-0.01市净率
0.00%股息率 TTM
-281.72%ROA
18.80052周最高
1.47量比
-26.97M净利润
396.53K总股本
-4.2173每股收益TTM
1.06Beta
-5396.85%ROE
1.90652周最低
14.44%振幅
100.00%毛利率
335.90K总市值
-7.11回报/风险
5.35%风险率
TradingKey VolitionRX Ltd股票评分
单位: USD 更新时间: 2026-07-27操作建议
VolitionRX Ltd当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名119/386位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价16.97。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
VolitionRX Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
VolitionRX Ltd亮点
亮点风险
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
业绩高增长
公司营业收入稳步增长，连续3年增长122.80%
业绩增长期
公司处于发展阶段，最新年度总收入1.73M美元
估值高估
公司最新PE估值-0.21，处于3年历史高位
机构减仓
最新机构持股1.13M股，环比减少15.69%
分析师目标
根据
5
位分析师
买入
评级
16.966
目标均价
+1596.60%
涨幅空间
VolitionRX Ltd新闻
即将为您带来更多新闻，敬请期待。。。
收益预测
分析师评级
根据
5
位分析师
买入
评级
16.966
目标均价
+1596.60%
涨幅空间
强力买入
买入
持有
卖出
强力卖出
同行比较
496
总数
6
中位数
7
平均值
公司名称
评级分布
分析师数
VolitionRX Ltd
VNRX
5
百济神州
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
艾昆纬
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
技术指标
移动平均线
指标
数值
方向
MA5
0.970
卖出
MA10
1.053
卖出
MA20
1.200
卖出
MA50
1.632
卖出
MA100
2.466
卖出
MA200
2.789
卖出
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
VolitionRX Ltd简介
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
公司代码VNRX
公司VolitionRX Ltd
CEOButera (Salvatore Thomas)
网址https://volition.com/
公司股东
相关品种
热门品种
常见问题
VolitionRX Ltd(VNRX)的当前股价是多少？
VolitionRX Ltd(VNRX)的当前股价是 0.85。
VolitionRX Ltd的股票代码是什么？
VolitionRX Ltd的股票代码是VNRX。
VolitionRX Ltd股票的52周最高点是多少？
VolitionRX Ltd股票的52周最高点是18.80。
VolitionRX Ltd股票的52周最低点是多少？
VolitionRX Ltd股票的52周最低点是1.91。
VolitionRX Ltd的市值是多少？
VolitionRX Ltd的市值是335.90K。
现在VolitionRX Ltd(VNRX)的股票是买入、持有还是卖出？
根据分析师评级，VolitionRX Ltd(VNRX)的总体评级为买入，目标价格为16.97。
VolitionRX Ltd(VNRX)股票的每股收益（EPS TTM）是多少
VolitionRX Ltd(VNRX)股票的每股收益（EPS TTM）是-4.37。